Overview
- Starter or oral GLP‑1 doses will be about $149 per month pending FDA approvals, with current injectables priced around $350 on TrumpRx and planned to decline to $245 over two years.
- Medicare will launch a mid‑2026 pilot covering defined cohorts for obesity and cardiometabolic benefits, with a $50 monthly copay for eligible enrollees.
- Eli Lilly and Novo Nordisk agreed to a roughly $245 monthly price for Medicare and for state Medicaid programs that opt in, while broader Medicaid participation will depend on state decisions.
- The TrumpRx direct‑to‑consumer site is slated to begin offering discounted GLP‑1s in January 2026, with government coverage timelines tied to the pilot’s rollout and FDA approvals for oral versions.
- Administration officials said the pricing commitments are paired with concessions to the companies, including tariff relief and expedited FDA review vouchers.